Novartis Phase III study indicates MF59® adjuvanted influenza vaccine, Fluad®, is 75 percent more efficacious than studied non- adjuvanted vaccines in young childrenDisclaimerThe foregoing release contains forward-looking statements that can be identified by terminology such as ―potential,‖―...
Novartis Phase III study indicates MF59® adjuvanted influenza vaccine, Fluad®, is 75 percent more efficacious than studied non-athe age of 5 in the United States (US) are hospitalized because of influenza complications[3].The associated reach up to 250 million US dollar...